Eli Lilly is about to report earnings. Here's what to expect
Eli Lilly is slated to report third-quarter earnings and revenue, which will likely be fueled by its obesity drug Zepbound and diabetes counterpart Mounjaro.
Eli Lilly is slated to report third-quarter earnings and revenue on Thursday, which will likely be fueled by its blockbuster obesity drug Zepbound and diabetes counterpart Mounjaro.
Here's what Wall Street is expecting, based on a survey of analysts by LSEG:
But investors will also be laser-focused on the launch of the company's obesity pill, Foundayo, which entered the market in April. Analysts forecast around $229 million in sales for the pill, StreetAccount estimates showed.
Lilly's massive diabetes and obesity windfall – and dominance over chief rival Novo – show no signs of slowing down, even as the company grapples with lower net prices in the U.S. The pharma giant is converting these historic profits into a major dealmaking spree, striking a deal to buy a psychedelics drugmaker in July and announcing plans to purchase three vaccine makers in May.
Not cross-checked yet
Only CNBC reports this story so far. We show it as a single source until another newsroom confirms it.
- CNBC29 Oct, 11:13
| Publisher CNBC (reference tier) | +82 |
| Detailed summary | +2 |
| Total | 84 |
Method: reports are grouped by the words of their headline and summary; each newsroom counts once; figures are read from the reports as published. Nothing here is written by an AI.